The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Ferric carboxymaltose (Ferinject®) has been accepted for restricted use for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. Use is restricted to administration by intravenous infusion in patients not receiving haemodialysis.
Omalizumab (Xolair®) has been accepted for restricted use in adults, adolescents (12 years of age and older) and children (6 to <12 years of age) with convincing IgE (immunoglobulin E) mediated asthma. Use is restricted to patients who are prescribed chronic systemic steroids and in whom all other treatments have failed. Treatment should be reassessed at 16 weeks and discontinued if there is not a marked improvement in overall asthma control.
Tapentadol prolonged-release (Palexia SR®) has been accepted for restricted use in the management of severe chronic pain in adults. Use is restricted to patients in whom morphine sulphate modified release has failed to provide adequate pain control or is not tolerated.
Triptorelin pamoate (Decapeptyl SR®) is accepted for patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration or treatment of metastatic prostate cancer. This new product allows for 6-monthly administration.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.